Literature DB >> 34982103

Bringing Alzheimer Disease Testing and Results Disclosure Into the 21st Century Cures Act.

Emily A Largent1, Angela R Bradbury2.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 34982103      PMCID： PMC8923901          DOI： 10.1001/jamaneurol.2021.4851

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN： 2168-6149            Impact factor:   18.302


× No keyword cloud information.
  5 in total

1.  Telemedicine and Medical Licensure - Potential Paths for Reform.

Authors:  Ateev Mehrotra; Alok Nimgaonkar; Barak Richman
Journal:  N Engl J Med       Date:  2021-02-20       Impact factor: 91.245

2.  Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results.

Authors:  Emily A Largent; Kristin Harkins; Christopher H van Dyck; Sara Hachey; Pamela Sankar; Jason Karlawish
Journal:  PLoS One       Date:  2020-02-13       Impact factor: 3.240

3.  Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab.

Authors:  Lawren VandeVrede; Daniel M Gibbs; Mary Koestler; Renaud La Joie; Peter A Ljubenkov; Karine Provost; David Soleimani-Meigooni; Amelia Strom; Elena Tsoy; Gil D Rabinovici; Adam L Boxer
Journal:  Alzheimers Dement (Amst)       Date:  2020-10-09

4.  Private payer coverage policies for ApoE-e4 genetic testing.

Authors:  Jalayne J Arias; Ana M Tyler; Michael P Douglas; Kathryn A Phillips
Journal:  Genet Med       Date:  2021-01-08       Impact factor: 8.822

5.  Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors.

Authors:  Jill S Goldman; Susan E Hahn; Jennifer Williamson Catania; Susan LaRusse-Eckert; Melissa Barber Butson; Malia Rumbaugh; Michelle N Strecker; J Scott Roberts; Wylie Burke; Richard Mayeux; Thomas Bird
Journal:  Genet Med       Date:  2011-06       Impact factor: 8.822
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.